The event will be held at the Aspen Chabad Jewish Community Center, at 435 West Main Street.
Discover what the future of healthcare holds from the medical pioneers themselves
The Gorlin Companies is proud to present our second annual Aspen Healthcare Summit. Our goal to insure that the world leaders in the healthcare industry have a platform in Aspen to share their knowledge and views in the advancement of Artificial Intelligence in the Healthcare Industry, the Opioid Crisis in America and The New Age of Drug Resistant Super Bugs.
The Gorlin Companies have supported medical science and innovative therapies for four decades. These companies have been on the leading edge of research and discovery worldwide. Every year the advancements in the diagnosis and treatment of serious and life-threatening diseases are rapidly evolving.
Please join us for this fascinating community discussion relating to the future of medical science and evolutionary treatments of diseases. You will have the opportunity to meet and talk to some of the most brilliant minds in the Healthcare Arena.
Chief of Staff for Gorlin Companies
Founder of Aspen Healthcare Summit
Our keynote speakers are medical experts and innovators
Deborah C Mash, PhD
Professor Emeritus of Neurology and Molecular and Cellular Pharmacology at the University of Miami Miller School of Medicine Founder and director of the University’s Brain Endowment Bank, one of six federated NIH NeuroBioBanks.
Held the Jeanne C. Levey endowed chair in the department of Neurology.
Has contributed to more than 300 published studies and monographs investigating drug addiction, neurodegenerative and neuropsychiatric diseases.
Michael Mansour, MD, PhD
Assistant Professor of Medicine at Harvard Medical School, and a Transplant Infectious Diseases Attending at the Division of Infectious Diseases at Massachusetts General Hospital.
Focused mainly on the care of solid and bone marrow transplant patients with infectious complications.
Maintains a basic research laboratory investigating the critical molecular mechanisms responsible for host immune responses to life-threatening fungal pathogens.
Developing innovative therapeutics to address the rising numbers of drug-resistant invasive fungal infections, often with mortality greater than 90%
Peter Haaland, PhD
Past Director of National Intelligence as Office Director for Safe and Secure Operations, Intelligence Advanced Research Projects Activity (IARPA).
Past Program Manager with the Defense Advanced Research Projects Agency (DARPA), where he created and managed multidisciplinary research and development.
Received Ph.D., M.A., and B.A. degrees in chemistry from Harvard, holds twelve U.S. Patents, and has published over forty peer-reviewed papers in scientific journals.
He served for ten years on active duty in the U.S. Air Force, including five as Associate Professor of Physics at the Air Force Institute of Technology.
Alan Altman, MD.
Please reach out to us if you have any questions about this year’s event.